Physician profile
Renato Alfonso
NPI 1184619017
$12,878.56
in general payments reported to CMS, 2019-2025
52 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $1,777 · 2021: $1,788 · 2022: $2,086 · 2023: $1,968 · 2024: $1,766 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,667.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,079.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,834.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,272.59 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $1,014.22 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $872.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $677.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $562.73 | 2019-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $561.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $464.20 | 2019-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $406.41 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.77 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $240.94 | 2020-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $232.91 | 2020-2024 | Spravato |
| Exact Sciences Corporation | $210.74 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $209.18 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renato Alfonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.